0.11 (-80.85%)
As of Jan 23, 2023
Source:
Our goal is to slow the progression of chronic kidney disease, or CKD, through the treatment of metabolic acidosis. We are a pharmaceutical company focused on the development and commercialization of our investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | 415-429-7800 |
| Industry | manufacturing |
| CEO | Gerrit Klaerner, Ph.D. |
| Website |